This Phase 1 study tests a new cell therapy for patients aged 12–75 with relapsed or refractory CD30-positive lymphomas, including Hodgkin lymphoma, NK and T cell lymphoma, and diffuse large B cell lymphoma (DLBCL).
Description
CD30-positive lymphomas are cancers that include Hodgkin lymphoma, NK and T cell lymphoma, and diffuse large B cell lymphoma (DLBCL). These diseases can be difficult to treat when they come back or don’t respond to standard therapies. This study uses a new type of cell therapy called CD30.CAR-EBVSTs. These are immune cells made from healthy donors that have been trained to recognize and attack cancer cells that carry the CD30 marker. The cells also target Epstein-Barr virus (EBV), which is linked to some lymphomas. This approach may offer a more precise and powerful treatment option. Researchers are also studying biomarkers and immune responses to better understand how the therapy works.
Eligibility
• Ages 12 to 75 • Diagnosis of CD30-positive lymphoma, including Hodgkin lymphoma, NK or T cell lymphoma, or DLBCL • Relapsed or refractory disease • Adequate organ function • Performance status of 0–2 Detailed inclusion and exclusion criteria are listed at clinicaltrials.gov.
To inquire about this trial, fill out our online referral form:
